HICCC receives $ 18 million grant from National Institute of Cancer -
outstanding basic research, a growing interest in translating discoveries into treatments, and a commitment to patients won the Herbert Irving Comprehensive cancer Center (HICCC) of Columbia University Medical Center (CMTC) and NewYork-Presbyterian Hospital $ 18 million over five years cancer Center National cancer Institute support grant (NCI). The grant renews the status of the center as one of only two NCI-designated Cancer Centers complete in New York and one of only three in the state of New York.
"Both clinical and research programs at the Herbert Irving Comprehensive Cancer Center have increased significantly in recent years, under the direction of Dr. Stephen Emerson, and this grant recognizes our potential to change the way cancer is diagnosed, treated and prevented, "said Lee Goldman, MD, MPH, Harold and Margaret Hatch University professor and dean of the faculties of health sciences and medicine at CMTC. "This renewal will ensure the continuity of our current research, patient care, and educational programs as we continue to add cancer researchers and clinicians at our extremely talented and dedicated team."
"the Herbert Irving Comprehensive cancer Center reflects our commitment to be a leader in the prevention, diagnosis and treatment of cancer," said Steven J. Corwin, MD, CEO of NewYork-Presbyterian Hospital. "There is still work to do, and NCI funding helps provide our physicians, nurses and staff resources to deliver the highest quality, safest and most patient-centered care. With this renewal of the grant, NewYork-Presbyterian, working with our doctors and Columbia University Medical Center, will be able to fulfill our commitment to transforming the full spectrum of cancer care to better serve patients and families facing a diagnosis of cancer. "
recent growth of HICCC included the recruitment of a number of prominent physicians and researchers (40 set during the last period of NCI funding), including the center's director, Stephen G. Emerson, MD, PhD, who joined in 2012 in its assessment, the NCI congratulated Dr. Emerson's leadership, noting that the cancer center is on a trajectory to achieve exemplary results under his leadership.
"We are delighted to be recognized once again as an outstanding Comprehensive Cancer Center by the National Cancer Institute." Said Dr. Emerson, the '56 Clyde and Helen Wu Professor of Immunology and professor of microbiology and immunology. "The national review team assessed the HICCC as exceptional or outstanding in almost all areas. This distinction recognizes and endorses the work of thousands of scientists, clinicians, educators and administrators in the fight against cancer."
Associate Director Gary Schwartz, MD, joined the center earlier this year as chief of hematology / oncology and was spearheading the expansion of clinical research and patient care . Dr. Schwartz, who came to Memorial Sloan Kettering Cancer Center (MSKCC), followed by a team of five experts from blood cancer led by Joseph Jurcic, MD, MSKCC who left to join NewYork-Presbyterian / Columbia in 2013. in 2012, Suzanne Lentzsch, MD, joined the medical center as director of the multiple myeloma and amyloidosis service Mapara Markus, MD, PhD, joined to lead the growth of blood medical center and marrow transplant program. Andrew Kung, MD, PhD, developer of the new processing center for Translational Therapeutics, joined in 2012 as Chief of Pediatric Hematology / Oncology. In 2011 Andrew Lassman, MD, became head of the neuro-oncology and medical director of clinical Office protocol data management center cancer. The main recruits such as these were made possible in part by a gift of $ 40 million in 2012 Herbert and Florence Irving benefactors and previous National Institutes of Health (NIH) and NCI grants.
The HICCC has over 250 members from Columbia six schools, 12 basic facilities and eight research programs. The Cancer Center investigators currently hold more than $ 0 million in NIH and NCI research grants. The productivity of its programs is reflected in the 3000 research and publications written by its members over the last NCI funding cycle. Some 33 percent of these papers are co-authored by researchers in the various programs and laboratories, demonstrating a strong culture of teamwork cancer center and interdisciplinary thinking
Among the Recent success of the research center are :. The work of the regulatory Cancer Networks Program, led by Jan Kitajewski, PhD, and Andrea Califano, Dr., to map genes that work together to drive aggressive forms of cancer; investigations of Breast Cancer Program, led by Dawn Hershman, MD, to characterize the short and long term risks associated with the treatment of breast cancer standard; Search multidisciplinary neuro-oncology team, led by Jeffrey Bruce, MD, of the brain-tumor systems biology, genetics, cell biology, and therapy; and the extensive work of collaboration between clinicians and basic scientists to identify drug targets for leukemia
The new patient care facilities include Irving Radiation Oncology Center, which opened in September 2013 . infusion centers both at NewYork-Presbyterian campus / Columbia in Washington Heights and Midtown ColumbiaDoctors at 51 W. 51st St. Irving and the bone marrow transplant unit in hospital, which opened in April 2014. HICCC doctors diagnosed and treated more than 3,500 new cases of cancer last year. The center offers cancer patients with access to some 0 ongoing clinical trials.
Charles B. Rangel, US Representative for the 13th Congressional District of New York, said: "I welcome the recent announcement of the National Cancer Institute that HICCC receive a grant of $ 18 million over the next five years. This significant investment reflects the commitment of HICCC find a cure for cancer and to provide outstanding patient care. I especially want to thank the medical team and dedicated support staff to put these HICCC a difference in the lives of people affected by cancer. "
EmoticonEmoticon